FlyteHealth offers a comprehensive, clinically rigorous Cardio-Kidney-Metabolic (CMK) care platform designed to address rising employer healthcare costs driven by obesity, prediabetes, diabetes, hypertension, and hyperlipidemia. FlyteHealth integrates lifestyle, medical management including pharmacotherapy (GLP-1 & alternative weight loss medications) and long-term maintenance to deliver durable clinical outcomes and a measurable return on investment. FlyteHealth’s coordinated model—validated independently by Milliman—achieves 86 percent medication adherence at 12 months and produces significant improvements across key biometrics over 24 months, including 15+% weight loss, 16+% reductions in systolic and diastolic blood pressure, 9+% decreases in LDL cholesterol and 13+% reductions in HbA1c..

For more information visit www.flytehealth.com.